Artificial expression constructs for selectively modulating gene expression in cortical excitatory neurons

Abstract

To provide an artificial expression construct for selectively regulating gene expression.SOLUTION: There is provided an artificial expression construct comprising (i) a concatemer comprising a specific sequence, (ii) a promoter, and (iii) a heterologous coding sequence, for selectively modulating gene expression in a selected central nervous system cell type. The artificial expression construct can be used to selectively express the synthetic gene or modulate gene expression, particularly in cortical excitatory neurons, including those predominantly within cortical layers 2 / 3, 4, 5, and 6, and having extracerebral (ET), intracerebral (IT), and pyramidal tract (PT) projections.SELECTED DRAWING: None

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Nos. 62 / 755,988, filed November 5, 2018, 62 / 806,600, filed February 15, 2019, 62 / 806,684, filed February 15, 2019, and 62 / 872,021, filed July 9, 2019, each of which is incorporated by reference in its entirety as if fully set forth herein.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under Grant 1R01-DA036909 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] Reference to sequence listing The sequence listing associated with this application is provided in text format in lieu of a hard copy and is incorporated herein by reference. The text file containing the sequence listing is named A166-0007PCT_ST25.txt. The text file is 597 KB, was created on November 5, 2019, and has been submitted electronically via EFS-Web.

[0004] The present disclosure provides artificial expression constructs for selectively driving gene expression in cortical excitatory neurons. The artificial expression constructs can be used to selectively express synthetic genes or modulate gene expression in cortical excitatory neurons, particularly those primarily within cortical layers 2 / 3, 4, 5, and 6, and those with extracerebral (ET), intracerebral (IT), and pyramidal tract (PT) processes. [Background technology]

[0005] To fully understand brain biology, it is necessary to distinguish and define distinct cell types, and to further study them, it is necessary to identify vectors that can selectively label and disrupt them. In mice, recombinase driver strains have been used to great effect to label cell populations that share marker gene expression. However, the creation, maintenance, and use of such strains to label cell types with high specificity can be expensive and often require triple transgenic crosses, which result in low frequencies of experimental animals. Furthermore, these tools require germline transgenic animals and are therefore not applicable to humans.

[0006] Recent advances in single-cell profiling, such as single-cell RNA-seq and investigations of neuronal electrophysiology and morphology, have revealed that many recombinant driver lines label a heterogeneous mixture of cell types, often including cells from multiple subclasses. For example, the Rbp4-Cre mouse driver line, commonly used to label layer 5 (L5) neurons, labels cells with very distinct connectivity patterns: L5 intratelencephalic (IT, also known as cortico-cortical) and pyramidal tract (PT, also known as cortico-subcortical) neurons. Summary of the Invention

[0007] The present disclosure provides artificial expression constructs that selectively drive gene expression in targeted central nervous system cell populations. Targeted central nervous system cell populations include cortical excitatory neurons, e.g., those primarily within cortical layers (L) 2 / 3, 4, 5, and / or 6, as well as those with extracerebral (ET) projections, intracerebral (IT) projections, and / or pyramidal tract (PT) projections. Certain artificial expression constructs disclosed herein target specific excitatory cell types, while others selectively drive gene expression across multiple excitatory neuron types.

[0008] For example, an artificial expression construct comprising a promoter, the eHGT_075h enhancer, and a gene encoding an expression product can result in selective gene expression in L2 / 3 IT cortical excitatory neurons.

[0009] Artificial expression constructs containing the promoter, Grik1_enhScnn1a-2, eHGT_058h, eHGT_058m, eHGT_439m, and / or eHGT_254h enhancer, and a gene encoding an expression product can result in selective gene expression in L4 IT cortical excitatory neurons.

[0010] Specific examples of artificial expression constructs containing a promoter, the mscRE4 enhancer, the linked mscRE4, and / or the linked mscRE16 enhancer, and a gene encoding an expression product can result in selective gene expression in L5 PT cortical excitatory neurons. Examples of these expression constructs include T502-057 (vAi3.0), 981 (vAi5.0), 1052 (vAi10.0), CN1818 (vAi128.0), CN2014 (vAi129.0), and vAi130.0.

[0011] Artificial expression constructs containing a promoter, a linked core of the mscRE4 enhancer, and a gene encoding an expression product can result in selective gene expression in L5 PT and L5 ET cortical excitatory neurons.

[0012] Artificial expression constructs containing a promoter, mscRE1, mscRE11, and / or mscRE16 enhancer, and a gene encoding an expression product can result in selective gene expression in L5 PT and L5 IT cortical excitatory neurons.

[0013] An artificial expression construct containing a promoter, the mscRE13 enhancer, and a gene encoding an expression product can result in selective gene expression in L6 IT cortical excitatory neurons.

[0014] Specific examples of artificial expression constructs containing a promoter, the mscRE10 enhancer, and a gene encoding an expression product can result in selective gene expression in L6 CT cortical excitatory neurons. Examples include 995 (vAi15.0).

[0015] An artificial expression construct containing a promoter, the eHGT_440h enhancer, and a gene encoding an expression product can result in selective gene expression in a subtype of L6b cortical excitatory neurons.

[0016] An artificial expression construct containing the promoter, the eHGT_078h enhancer, and a gene encoding the expression product can result in selective gene expression in L2 / 3 IT, L4 IT, L5 IT, L5 NP, and L5 PT cortical excitatory neurons.

[0017] Selective expression of genes encoding expression products can be achieved in L2 / 3 IT, L5 IT, and L6b neurons using the 1036(vAi16.0) artificial expression construct described herein, which contains the mscRE10 enhancer.

[0018] Selective expression of genes encoding expression products can be achieved in L2 / 3 IT, L5 PT, L6 CT, and L6b neurons using the 988 (vAi7.1), 1010 (vAi6.1), and / or 1011 (vAi7.2) artificial expression constructs described herein. These constructs contain the mscRE4 enhancer.

[0019] Pan-excitatory and / or widespread expression in cortical excitatory neurons can be selectively achieved using an artificial expression construct comprising a promoter, eHGT_073h, eHGT_073m, eHGT_077h, and / or eHGT_078m enhancer, and a gene encoding the expression product. In certain embodiments, pan-excitatory expression refers to expression in at least four types of cortical excitatory cells that is limited to non-expression in inhibitory cells and glial cells.

[0020] The artificial expression constructs described herein can also label other distinct cell types. For example, in addition to L5 PT cells, an artificial expression construct containing a promoter, an mscRE4 enhancer, and a gene encoding an expression product can result in gene expression in the CEAc, substantia nigra, pars compacta (SNc), and subcortical populations in the Prostaglandin S (ProS). Similarly, in addition to L5 PT cells, an artificial expression construct containing a promoter, a junction core of the mscRE4 enhancer, and a gene encoding an expression product can result in gene expression in the subiculum, CA1 pyramidal neurons, a subset of dentate gyrus granule cells, scattered striated neurons, and rare cerebellar Purkinje cells.

[0021] As indicated by the preceding discussion, certain artificial expression constructs disclosed herein include engineered enhancers, such as the concatenated cores of the mscRE4, eHGT_078h, and eHGT_078m enhancers, as well as a concatemer of the mscRE4 and mscRE16 enhancers. The functional 155-base pair (bp) core of the mscRE4 enhancer (SEQ ID NO: 29) was concatenated (SEQ ID NO: 30) in conjunction with the MscRE4 enhancer to minimize the size required to drive gene expression. Despite being a 3x concatemer, SEQ ID NO: 30 is shorter in length than the original mscRE4 enhancer (SEQ ID NO: 28, which contains 555 bp). When used to construct artificial expression constructs such as rAAV, such concatemers allow more space for enhancer-linked cargo genes, which is highly desirable, for example, in gene therapy vectors. For example, many therapeutic cargo genes are too large to fit into AAV vector design, making space (sequence length) a valuable commodity.

[0022] As described in more detail throughout this disclosure, certain artificial expression constructs disclosed herein include T502-050, T502-054, vAi34.0, vAi33.2, vAi45.0, vAi1.0, T502-057, T502-059, TG978, TG981, TG988, TG995, TG996, TG999, TG1002, TG1010, TG1011, TG1021, TG1 036, TG1037, TG1038, TG1046, TG1047, TG1048, TG1049, TG1050, TG1052, CN1402, CN1457, CN1818, CN1416, CN1452, CN1461, CN1454, CN1456, CN1772, CN1427, CN1466, CN1954, CN1955, CN2137, CN2139, and CN2014.

[0023] Many of the drawings submitted herein are better understood in color, and applicants reserve the right to consider color versions of the drawings as part of the original submission and to present color images of the drawings in subsequent proceedings. [Brief explanation of the drawings]

[0024] [Figure 1A] TG978 (vAi4.1). Enhancer mscRE4 (eAi3.0). Representative epifluorescence images of mscre4-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 1B] TG978 (vAi4.1). Enhancer mscRE4 (eAi3.0). Representative epifluorescence images of mscre4-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 1C] TG978 (vAi4.1). Enhancer mscRE4 (eAi3.0). Single-cell RNA sequencing analysis of tdTomato-positive cells isolated from the primary visual cortex (V1) of mscre4-FlpO-infected Ai65F mice. L2 / 3, layer 2 / 3; L5, layer 5; wm, white matter. [Figure 2]TG981 (vAi5.0) enhancer mscRE4 (eAi3.0). Representative epifluorescence image of mscre4-EGFP-WPRE viral expression in the brain of a wild-type mouse. Brain sections were stained with anti-GFP antibody to visualize GFP fluorescence. [Figure 3] TG988 (vAi7.1) enhancer mscRE4 (eAi3.0). (A) Representative epifluorescence image of the mscre4-tTA2 virus induced expression in the brain of an Ai63 reporter mouse. Brain sections were stained with an anti-dsred antibody to reveal tdTomato fluorescence. (B) The mscre4-tTA2 virus was directly injected into the brain of an Ai63 mouse, and native tdTomato fluorescence was imaged within the primary visual cortex (V1 or VISp). Note that imaging parameters between the two images may differ. L2 / 3, layer 2 / 3; L5, layer 5; wm, white matter. [Figure 4] A and B are representative epifluorescence images of the mscre4-iCre virus induced in the brain of TG1010 (vAi6.1) enhancer mscRE4 (eAi3.0). Ai14 reporter mice. L5, layer 5; L6, layer 6; wm, white matter. [Figure 5] A and B are representative epifluorescence images of the mscre4-tTA2 virus induced in the brain of TG1011 (vAi7.2) enhancer mscRE4 (eAi3.0) Ai63 reporter mice. [Figure 6] TG1021 (vAi8.0Cre) enhancer mscRE4 (eAi3.0). Representative epifluorescence image of Mscre4-Cre-WPRE virus induced expression in the brain of Ai14 reporter mice. [Figure 7] TG1052 (vAi10.0) enhancer 4XmscRE16 (eAi11.1). Representative epifluorescence image of 4Xmscre16-EGFP-WPRE virus expression in the brain of a wild-type mouse. The virus was delivered directly into the brain by stereotactic injection. [Figure 8]A and B are representative epifluorescence images of mscre10-EGFP-WPRE viral expression in the brain of a wild-type mouse. [Figure 9A] TG1036 (vAi16.0) enhancer mscRE10 (eAi6.0). Representative epifluorescence images of mscre10-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 9B] TG1036 (vAi16.0) enhancer mscRE10 (eAi6.0). Representative epifluorescence images of mscre10-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 9C] TG1036 (vAi16.0) enhancer mscRE10 (eAi6.0). Single-cell RNA sequencing analysis of tdTomato-positive cells isolated from the primary visual cortex (V1) of mscre10-FlpO-WPRE-infected Ai65F mice. [Figure 10] A and B are representative epifluorescence images of the mscre10-tTA2-WPRE virus expressing TG1048 (vAi18.0) enhancer mscRE10 (eAi6.0) in the brain of Ai63 reporter mice. [Figure 11] TG996 (vAi19.0) enhancer mscRE11 (eAi7.0). Representative epifluorescence image of mscre11-EGFP-WPRE virus in the brain of a wild-type mouse. Brain sections were stained with anti-GFP antibody to reveal GFP fluorescence. [Figure 12] A and B show TG999 (vAi21.0) enhancer mscRE13 (eAi9.0). Representative epifluorescence images of the mscre13-EGFP-WPRE virus in the brain of a wild-type mouse. Brain sections were stained with anti-GFP antibody to reveal GFP fluorescence. [Figure 13A] Representative epifluorescence images of the mscre13-FlpO-WPRE virus induced expression of TG1037 (vAi22.0) enhancer mscRE13 (eAi9.0) in the brain of Ai65F reporter mice. [Figure 13B] TG1037 (vAi22.0) enhancer mscRE13 (eAi9.0). (B) Single-cell RNA sequencing analysis of tdTomato-positive cells isolated from the primary visual cortex (V1) of mscre13-FlpO-WPRE-infected Ai65F mice. Cell types from top to bottom are Lamp5 Pich2 Dock5, Lamp5 Lsp1, Vip Chat Htr1f, Sst Tac1 Htr1d, Sst Calb2 Pdlm5, Sst Nr2f2 Necab, Pvalb Sema3e Kank4, Pvalb Rein Itm2a, L2 / 3 IT VISp Rred, L2 / 3 IT VISp Adamts2, L2 / 3 IT VISp Agmat, L2 / 3 IT ALM Sla, L6 IT VISp Penk Col27a1, L6 IT VISp Penk Fst, L6 IT VISp Col18a1, L5 IT VISp Hsd11b1 Endou, L5 IT VISp Whrn Tox2, L5 IT VISp Col27a1, L5 PT VISp C1qI2 Cdh13, L5 PT VISp Krt80, L6 IT These include VISp Car3, L4 IT VISp Rspo1, intronic VISp L5 Endou, L6 CT VISp Gpr139, L6 CT VISp Ctxn3 Brinp3, L6 CT VISp Ctxn3 Sla, and L6b VISp Mup5. [Figure 14] Representative epifluorescence image of the mscre13-iCre-WPRE virus induced expression of TG1046 (vAi23.0) enhancer mscRE13 (eAi9.0) in the brain of Ai14 reporter mice. [Figure 15] Representative epifluorescence images of the mscre13-tTA2-WPRE virus induced expression in the brain of Ai63 reporter mice. [Figure 16]A and B show representative epifluorescence images of TG1002 (vAi26.0) enhancer mscRE16 (eAi11.0) and mscre16-EGFP-WPRE virus in the brain of a wild-type mouse. Brain sections were stained with anti-GFP antibody to reveal GFP fluorescence. [Figure 17A] Representative epifluorescence images of TG1038 (vAi27.0) enhancer mscRE16 (eAi11.0) and mscre16-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 17B] Representative epifluorescence images of TG1038 (vAi27.0) enhancer mscRE16 (eAi11.0) and mscre16-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 17C] TG1038 (vAi27.0) enhancer mscRE16 (eAi11.0). Single-cell RNA sequencing analysis of tdTomato-positive cells isolated from the primary visual cortex (V1) of mscre16-FlpO-WPRE-infected Ai65F mice. Cell types from top to bottom are Lamp5 Pich2 Dock5, Lamp5 Lsp1, Sst Mme Fam114a1, L2 / 3 IT VISp Agmat, L6 IT VISp Agmat, L6 IT VISp Penk Fst, L6 IT VISp Col23a1, Adamts2, L6 IT VISp Col18a1, L5 IT VISp Hsd11b1 Endou, L5 IT VISp Whrn Tox2, L5 IT VISp Batf3, L5 IT VISp Col6a1 Fezf2, L5 IT ALM Tmem163 Arhgap25, L5 IT ALM Cpa6 Gpr88, L5 PT VISp C1qqI2 Cdh13, L5 PT VISp Krt80, Intronic VISp L5 Endou, L6CT VISp Ctxn3 These include Brinp3, L6CT VISp Ctxn3 Sla, and LowAqp4. [Figure 18]TG1047 (vAi28.0) enhancer (mscRE16 (eAi11.0). Representative epifluorescence image of the mscre16-iCre-WPRE virus induced expression in the brain of Ai14 reporter mice. [Figure 19A] Representative epifluorescence images of the mscre16-tTA2-WPRE virus induced expression of TG1050 (vAi29.0) enhancer mscRE16 (eAi11.0) in the brain of Ai63 reporter mice. [Figure 19B] Representative epifluorescence images of the mscre16-tTA2-WPRE virus induced expression of TG1050 (vAi29.0) enhancer mscRE16 (eAi11.0) in the brain of Ai63 reporter mice. [Figure 20] TG1149 / (T502-050; vAi33.0) enhancer Grik1-enhScnn1a-2 (eAi14.0). Representative confocal images of Hsp68-EGFP-WPRE-Grik1-enhScnn1a-2 virus induced expression in the brain of wild-type mice. [Figure 21] A and B are representative confocal images of TG1108 (vAi34.0) enhancer Scnn1a (Grik1) (eAi14.0) and Scnn1a (Grik1)-FlpO-WPRE viruses induced in the brains of Ai65 reporter mice. [Figure 22] A, B: TG1114 (vAi33.2) enhancer Scnn1a (Grik1) (eAi14.0). Representative epifluorescence images of Scnn1a (Grik1)-EGFP-WPRE virus in the brain of a wild-type mouse. Brain sections were stained with anti-GFP antibody to reveal GFP fluorescence. [Figure 23] TG1109 (vAi45.0) enhancer mscRE12 (eAi8.0). Representative epifluorescence image of mscre12-FlpO-WPRE virus induced expression in the brain of Ai65F reporter mice. [Figure 24A] CN1402(vAi106.0) enhancer eHGT_058h(eAi106.0). (A) Fluorescent expression of CN1402 shown in whole mouse brain in sagittal sections. [Figure 24B] CN1402 (vAi106.0) enhancer eHGT_058h (eAi106.0). High-resolution image (left) showing non-overlapping CN1402 SYFP fluorescence (red) and inhibitory marker Gad1 mRNA expression (white). The image on the right shows near-competitive overlap of CN1402 SYFP fluorescence (red) and cortical excitatory marker Slc17a7 mRNA expression (white). [Figure 24C] CN1402 (vAi106.0) enhancer eHGT_058h (eAi106.0). Quantification of the specificity of CN1402 SYFP fluorescence in ALM and V1 mouse cortical regions based on multiplexed FISH data. Single-cell transcriptomic characterization of SYFP-fluorescent cells isolated from mouse V1. [Figure 24D-1]CN1402 (vAi106.0) enhancer eHGT_058h (eAi106.0). After single-cell gene expression analysis, cells were mapped to existing classifications of mouse cell types. The position of the blue circle reflects the extent of single-cell mapping (towards the terminal lobe), and the size of the blue circle reflects the number of single cells mapped to that point in the hierarchy. The downward-projecting bar reflects the number of cells mapping to that terminal branch of the cell type classification. Cells listed from left to right include 169 L2 / 3 IT VISp Rrad, 168 L2 / 3 IT VISp Adamts2, 167 L2 / 3 IT VISp Agmat, 164 L4 IT VISp Rspo1, 163 L5 IT VISp Hsd11b1 Endou, 162 L5 IT VISp Whrn Tox2, 160 L5 IT VISp Batf3, 158 L5 IT VISp Col6a1 Fezf2, 157 L5 IT VISp Col27a1, 154 L6 IT VISp Penk Col27a1, 153 L6 IT VISp Penk Fst, 152 L6 IT VISp Col23a1 Adamts2, 149 L6 IT VISp Col18a1, 146 L6 IT VISp Car3, 144 L5 PT VISp Chrna6, 143 L5 PT VISp Lgr5, 142 L5 PT VISp C1qI2 PTgfr, 141 L5 PT VISp C1qI2 Cdh13, 140 L5 PT VISp Krt80, 134 L5 NP VISp Trhr Cpne7, 133 L5 NP VISp Trhr Met, 131 L6 CT Nxph2 Sla, 130 L6 CT VISp Krt80 Sla, 128 L6 CT VISp Nxph2 Wls, 127 L6 CT VISp Ctxn3 Brinp3, 126 L6 CT VISp Ctxn3 Sla, 122 L6 CT VISp Gpr139, 120 L6b Col8a1 Rprm, 119 L6b VISp Mup5, 118 L6b VISp Col8a1 Rxfp1, 115 L6b P2ry12, 114 L6b VISp Crh, 110 Lamp5 Krt73, 109 Lamp5 Fam19a1Pax6、108 Lamp5 Fam19a1 Tmem182、106 Lamp5 Ntn1 Npy2r、105 Lamp5 Plch2 Dock5、101 Lamp5 Lsp1、100 Lamp5 Lhx6 97 Sncg Slc17a8、96 Sncg Vip Nptx2、95 Sncg Gpr50、93 Vip Itih5、90 Serpinf1 Clrn1、89 Serpinf1 Aqp5 Vip、85 Vip Igfbp6 Car10、84 Vip Igfbp6 Pltp、82 Vip Lmo1 Fam159b、81 Vip Lmo1 Myl1、79 Vip Igfbp6 Mab21I1、78 Vip Arhgap36 Hmcn1、77 Vip Gpc3 Slc18a3、74 Vip Ptprt Pkp2、73 Vip Rspo4 Rxfp1 Chat、71 Vip Lect1 Oxtr、70 Vip Rspo1 Itga4、67 Vip Chat Htr1f、66 Vip Pygm C1qI1、61 Vip CrispId2 Htr2c、60 Vip CrispId2 Kcne4、58 Vip Col15a1 Pde1a、54 Sst Chodl、53 Sst Mme Fam114a1、52 Sst Tac1 Htr1d、50 Sst Tac1 Tacr3、49 Sst Calb2 Necab1、48 Sst Calb2 Pdlim5、46 Sst Nr2f2 Necab1、45 Sst Myh8 Etv1、44 Sst Chrna2 Glra3、42 Sst Myh8 Pibin、40 Sst Chrna2 Ptgdr、39 Sst Tac2 Myh4、37 Sst Hpse Sema3c、36 Sst Hpse Cbln4、34 Sst Crhr2 Efemp1、33 Sst Crh 4930553C11Rik、31 Sst Esrn1、29 Sst Tac2 Tacstd2、28 Sst Rxfp1 Eya1、27 Sst Rsfp1 Prdm8、23 Sst Nts、21 Pvalb Gabrg1、20 Pvalb Th Sst、18 Pvalb Calb1 Sst、17 Pvalb Akr1c18 Ntf3、16 Pvalb Sema3eKank4, 14 Pvalb Gpr149 IsIr, 11 Pvalb Reln Itm2a, 10 Pvalb Reln Tac1, 9 Pvalb Tpbg, 4 Pvalb Vipr2, 1 Meis2 Adamts19, 170 Astro Aqp4, 171 OPC Pdgfra Grm5, 173 Oligo Serpinb1a, 174 Oligo Synpr, 175 VLMC Osr1 Cd74, 176 VLMC Osr1 Mc5r, 177 VLMC Spp1 Col15a1, 178 Peri Kcni8, 179 SMC Acta2, 180 Endo Ctla2a, and 181 Microglia Siglech are included. [Figure 24D-2]CN1402 (vAi106.0) enhancer eHGT_058h (eAi106.0). After single-cell gene expression analysis, cells were mapped to existing classifications of mouse cell types. The position of the blue circle reflects the extent of single-cell mapping (towards the terminal lobe), and the size of the blue circle reflects the number of single cells mapped to that point in the hierarchy. The downward-projecting bar reflects the number of cells mapping to that terminal branch of the cell type classification. Cells listed from left to right include 169 L2 / 3 IT VISp Rrad, 168 L2 / 3 IT VISp Adamts2, 167 L2 / 3 IT VISp Agmat, 164 L4 IT VISp Rspo1, 163 L5 IT VISp Hsd11b1 Endou, 162 L5 IT VISp Whrn Tox2, 160 L5 IT VISp Batf3, 158 L5 IT VISp Col6a1 Fezf2, 157 L5 IT VISp Col27a1, 154 L6 IT VISp Penk Col27a1, 153 L6 IT VISp Penk Fst, 152 L6 IT VISp Col23a1 Adamts2, 149 L6 IT VISp Col18a1, 146 L6 IT VISp Car3, 144 L5 PT VISp Chrna6, 143 L5 PT VISp Lgr5, 142 L5 PT VISp C1qI2 PTgfr, 141 L5 PT VISp C1qI2 Cdh13, 140 L5 PT VISp Krt80, 134 L5 NP VISp Trhr Cpne7, 133 L5 NP VISp Trhr Met, 131 L6 CT Nxph2 Sla, 130 L6 CT VISp Krt80 Sla, 128 L6 CT VISp Nxph2 Wls, 127 L6 CT VISp Ctxn3 Brinp3, 126 L6 CT VISp Ctxn3 Sla, 122 L6 CT VISp Gpr139, 120 L6b Col8a1 Rprm, 119 L6b VISp Mup5, 118 L6b VISp Col8a1 Rxfp1, 115 L6b P2ry12, 114 L6b VISp Crh, 110 Lamp5 Krt73, 109 Lamp5 Fam19a1Pax6、108 Lamp5 Fam19a1 Tmem182、106 Lamp5 Ntn1 Npy2r、105 Lamp5 Plch2 Dock5、101 Lamp5 Lsp1、100 Lamp5 Lhx6 97 Sncg Slc17a8、96 Sncg Vip Nptx2、95 Sncg Gpr50、93 Vip Itih5、90 Serpinf1 Clrn1、89 Serpinf1 Aqp5 Vip、85 Vip Igfbp6 Car10、84 Vip Igfbp6 Pltp、82 Vip Lmo1 Fam159b、81 Vip Lmo1 Myl1、79 Vip Igfbp6 Mab21I1、78 Vip Arhgap36 Hmcn1、77 Vip Gpc3 Slc18a3、74 Vip Ptprt Pkp2、73 Vip Rspo4 Rxfp1 Chat、71 Vip Lect1 Oxtr、70 Vip Rspo1 Itga4、67 Vip Chat Htr1f、66 Vip Pygm C1qI1、61 Vip CrispId2 Htr2c、60 Vip CrispId2 Kcne4、58 Vip Col15a1 Pde1a、54 Sst Chodl、53 Sst Mme Fam114a1、52 Sst Tac1 Htr1d、50 Sst Tac1 Tacr3、49 Sst Calb2 Necab1、48 Sst Calb2 Pdlim5、46 Sst Nr2f2 Necab1、45 Sst Myh8 Etv1、44 Sst Chrna2 Glra3、42 Sst Myh8 Pibin、40 Sst Chrna2 Ptgdr、39 Sst Tac2 Myh4、37 Sst Hpse Sema3c、36 Sst Hpse Cbln4、34 Sst Crhr2 Efemp1、33 Sst Crh 4930553C11Rik、31 Sst Esrn1、29 Sst Tac2 Tacstd2、28 Sst Rxfp1 Eya1、27 Sst Rsfp1 Prdm8、23 Sst Nts、21 Pvalb Gabrg1、20 Pvalb Th Sst、18 Pvalb Calb1 Sst、17 Pvalb Akr1c18 Ntf3、16 Pvalb Sema3eKank4, 14 Pvalb Gpr149 IsIr, 11 Pvalb Reln Itm2a, 10 Pvalb Reln Tac1, 9 Pvalb Tpbg, 4 Pvalb Vipr2, 1 Meis2 Adamts19, 170 Astro Aqp4 171 OPC Pdgfra Grm5, 173 Oligo Serpinb1a, 174 Oligo Synpr, 175 VLMC Osr1 Cd74, 176 VLMC Osr1 Mc5r, 177 VLMC Spp1 Col15a1, 178 Peri Kcni8, 179 SMC Acta2, 180 Endo Ctla2a, and 181 Microglia Siglech. [Figure 25A] CN1457 (vAi107.0) enhancer eHGT_078h (eAi107.0). Fluorescent expression of CN1457 shown in whole mouse brain in sagittal sections. [Figure 25B] CN1457 (vAi107.0) enhancer eHGT_078h (eAi107.0). High-resolution image (left) showing non-overlapping CN1457 SYFP fluorescence (red) and inhibitory marker Gad1 mRNA expression (white). The image on the right shows near-competitive overlap of CN1457 SYFP fluorescence (red) and cortical excitatory marker Slc17a7 mRNA expression (white). [Figure 25C] CN1457 (vAi107.0) enhancer eHGT_078h (eAi107.0). Quantification of the specificity of CN1457 SYFP fluorescence in the ALM and V1 mouse cortical regions based on multiplexed FISH data. [Figure 25D-1]CN1457 (vAi107.0) enhancer eHGT_078h (eAi107.0). Single-cell transcriptional characterization of SYFP fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, cells were mapped to existing classifications of mouse cell types. The position of the blue circle reflects the extent of single-cell mapping (toward the terminal lobe), and the size of the blue circle reflects the number of single cells mapped to that point in the hierarchy. The downward-projecting bar reflects the number of cells mapping to that terminal branch of the cell type classification. Cells are the same as those listed in the figure brief in Figure 24D. [Figure 25D-2] CN1457 (vAi107.0) enhancer eHGT_078h (eAi107.0). Single-cell transcriptional characterization of SYFP fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, cells were mapped to existing classifications of mouse cell types. The position of the blue circle reflects the extent of single-cell mapping (toward the terminal lobe), and the size of the blue circle reflects the number of single cells mapped to that point in the hierarchy. The downward-projecting bar reflects the number of cells mapping to that terminal branch of the cell type classification. Cells are the same as those listed in the figure brief in Figure 24D. [Figure 26] CN1416 (vAi108.0) enhancer eHGT_058m (eAi108.0). (A) Fluorescent expression of CN1416 shown in whole mouse brain in sagittal sections. (B) High-resolution image (left) showing non-overlapping CN1416SYFP fluorescence (red) and inhibitory marker Gad1 mRNA expression (white). The image on the right shows near-competitive overlap of CN1416SYFP fluorescence (red) and cortical excitatory marker Slc17a7 mRNA expression (white). (C) Quantification of the specificity of CN1416SYFP fluorescence in the ALM and V1 mouse cortical regions based on multiplexed FISH data. [Figure 27]CN1452 (vAi111.0) enhancer eHGT_073h (eAi111.0). (A) Fluorescent expression of CN1452 shown in whole mouse brain in sagittal sections. (B) Grayscale fluorescent image of DAPI and mFISH image of Gad1, Pvalb, Sst, SYFP (CN1452), and Vip mRNA in mouse visual cortex. (C) Co-staining of SYFP (CN1452) and Gad1 shows that only 7% of Gad1+ cells overlap with SYFP. N=43 cells from 1 animal. [Figure 28] CN1461 (vAi112.0) enhancer eHGT_073m (eAi112.0). (A) Fluorescent expression of CN1461 shown in whole mouse brain in sagittal sections. (B) Grayscale fluorescent image of DAPI and mFISH image of Gad1, Pvalb, Sst, SYFP (CN1461), and Vip mRNA in mouse visual cortex. (C) Co-staining of SYFP (CN1461) and Gad1 shows that only 1.5% of Gad1+ cells overlap with SYFP. N = 130 cells from 1 animal. [Figure 29] CN1454 (vAi113.0) enhancer eHGT_075h (eAi113.0). (A) Fluorescent expression of CN1454 shown in whole mouse brain in sagittal sections. (B) High-resolution image (left) showing non-overlapping CN1454 SYFP fluorescence (red) and inhibitory marker Gad1 mRNA expression (white). The image on the right shows near-competitive overlap of CN1454 SYFP fluorescence (red) and cortical excitatory marker Slc17a7 mRNA expression (white). (C) Quantification of the specificity of CN1454 SYFP fluorescence in the V1 mouse cortical region based on multiplexed FISH data. [Figure 30]CN1456 (vAi114.0) enhancer eHGT_077h (eAi114.0). (A) Fluorescent expression of CN1402 shown in whole mouse brain in sagittal sections. (B) High-resolution image (left) showing non-overlapping CN1402 SYFP fluorescence (red) and inhibitory marker Gad1 mRNA expression (white). The image on the right shows near-competitive overlap of CN1402 SYFP fluorescence (red) and cortical excitability marker Slc17a7 mRNA expression (white). (C) Quantification of the specificity of CN1402 SYFP fluorescence in the ALM and V1 mouse cortical regions based on multiplexed FISH data. Single-cell transcriptomic characterization of SYFP-fluorescent cells isolated from mouse V1. (D) After single-cell gene expression analysis, cells were mapped to an existing classification of mouse cell types. The position of the blue circle reflects the extent of single-cell mapping (towards the terminal lobe), and the size of the blue circle reflects the number of single cells mapped to that point in the hierarchy. The downward projecting bars reflect the number of cells mapping to that terminal branch of the cell type classification scheme. [Figure 31A] CN1818 (vAi128.0) enhancer mscRE4 (3xCore) (eAi3.2). Expression of construct CN1818 examined by native fluorescence microscopy of cells labeled by retro-orbital injection. [Figure 31B] CN1818 (vAi128.0) enhancer mscRE4 (3xCore) (eAi3.2). Expression of construct CN1818 was tested by hairpin chain reaction (HCR) RNA FISH targeting SYFP2 (derived from viral expression), Fam84b (expressed in L5 ET cells), and Rorb (expressed in L4 IT and L5 IT cells). FISH revealed a 78% specificity rate in situ (62 Fam84b+ and SYFP2+ / 80 total SYFP2+). [Figure 32A] CN2014 (vAi129.0) enhancer mscRE4 (eAi3.0). Expression of construct CN2014 examined by native fluorescence microscopy of cells labeled by retro-orbital injection. [Figure 32B]CN2014 (vAi129.0) enhancer mscRE4 (eAi3.0). Expression of construct CN2014 was tested by hairpin chain reaction (HCR) RNA FISH targeting SYFP2 (derived from viral expression), Fam84b (expressed in L5 ET cells), and Rorb (expressed in L4 IT and L5 IT cells). FISH revealed an 85% specificity rate in situ (45 Fam84b+ and SYFP2+ / 53 total SYFP2+). [Figure 33] CN1427 (vAi130.0) enhancer mscRE4 (4x) (eAi3.1). Native tdTomato fluorescent expression in the V1 region of mouse brain slices. CN1427 serotype PHPeB virus was delivered by retro-orbital injection with analysis of reporter transgene expression 40 days after injection. [Figure 34] CN1466 (vAi131.0) enhancer eHGT_078m (eAi128.0). (A) Expression of vector CN1466 (green) in mouse neocortical brain slice cultures after 25 days in vitro and 15 days post-infection. Mutually exclusive labeling of CN1466-labeled neurons (green) and GABAergic neurons (red). (B) Expression of vector CN1466 in human neocortical brain slice cultures at 9 days in vitro and 9 days post-infection. Extensive pyramidal neuron labeling was observed. [Figure 35] CN2139 (vAi134.0) enhancer eHGT_439m (eAi131.0). Expression of vector CN2139 in mouse brain by retro-orbital delivery. Brain slices were subjected to fixed tissue immunohistochemistry using anti-GFP and anti-CTIP2 antibodies. Virus-labeled cells were observed in L4 of the neocortex. [Figure 36] CN2137 (vAi135.0) enhancer eHGT_440h (eAi132.0). Expression of vector CN2137 in mouse brain by retro-orbital delivery. Brain slices were subjected to fixed tissue immunohistochemistry using anti-GFP and anti-CTIP2 antibodies. Virus-labeled cells were observed in L6b of the neocortex. [Figure 37](A) CN1954 (vAi132.0) Enhancer eHGT_078h (3x core) (eAi129.0). Expression of vector CN1954 in mouse neocortical brain slice cultures at 27 days in vitro and 20 days post-infection. (B) CN1955 (vAi133.0) Enhancer eHGT_078m (3x core) (eAi130.0). Expression of vector CN1955 in mouse neocortical brain slice cultures at 27 days in vitro and 20 days post-infection. [Figure 38] (A) vAi1.0 enhancer mscRE1 (eAi1.0). A) Expression of construct mscRE1-SYFP2 examined by natural fluorescence imaging of retro-orbital injection. (B) T502-059 (vAi2.0) enhancer mscRE1 (eAi2.0). A) Expression of construct mscRE3-SYFP2 examined by natural fluorescence imaging of retro-orbital injection. [Figure 39] A-D, T502-057 (vAi3.0) enhancer mscRE4 (eAi3.0). Expression of the construct mscRE4-SYFP2 tested by native fluorescence imaging of retro-orbital injection. [Figure 40] Cell Source and Quality Control (QC Statistics). Bar plot showing the number of cells flagged for each combination of QC criteria. N, number of cells collected. Unique fragments is the number of uniquely mapped fragments used in the analysis and was used for the first QC cutoff of >1e4 unique fragments. The fraction of fragments overlapping with the Encyclopedia of DNA Elements (CODE) DNase-seq peak was calculated using uniquely mapped fragments and used for the second QC cutoff of >0.25. The fraction of fragments >250 bp in length was calculated using unique fragments and provided a third QC cutoff of >0.1. [Figure 41]Overview of enhancer discovery for viral tools. To construct cell type-specific labeling tools, we isolated cells from adult mouse cortex and performed a single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq). Samples were clustered and compared with single-cell RNA sequencing (scRNA-seq) datasets to identify clusters. Single cells matching the same transcriptome type were then pooled, and the genomes were searched for type-specific putative enhancers. These regions were cloned upstream of a minimal promoter in an adeno-associated virus (AAV) genome backbone, which was used to generate self-complementary adeno-associated virus vectors (scAAV) or recombinant adeno-associated virus vectors (rAAV). These viral tools were delivered retroorbitally or stereotaxically to label specific cortical populations. In cells with matching cell types, enhancers recruit their cognate transcription factors to drive cell type-specific expression. In other cells, the viral genome is present but transcripts are not expressed. However, not all enhancers work as expected, so enhancer constructs need to be tested for specificity. [Figure 42] Example of fluorescence-activated cell sorting (FACS) gating. (4A) All FACS sorting followed a similar gating strategy: morphology and debris removal using forward scatter area (FSC-A) and side scatter area (SSC-A); doublet / multiplet removal using forward scatter width (FSC-W) × forward scatter height (FSC-H) and side scatter width (SSC-W) × side scatter height (SSC-H) gating; and live cell selection with or without fluorescent labeling using 4',6-diamidin-2-phenylindole (DAPI) and fluorophore signaling. This panel shows an example of gating for direct fluorophore labeling of cells from injection of mscRE4-SYFP2. [Figure 43]Comparison of the Gm12878 platform. Comparison of FACS-sorted scATAC-seq libraries with those previously generated using Fluidigm C1 (Buenrostro et al., Nature, 523 (2015)), sci-ATAC-seq (Cusanovich et al., Science, 348 (2015) and Pliner et al., Mol. Cell, 71 (2018)), or droplet-based indexing (10X Genomics) enabled data from a common cell line, human Gm12878 cells. For these comparisons, scATAC-seq data were generated using a FACS-based method for 60 Gm12878 cells. For each published dataset, raw data were obtained from GEO and aligned and analyzed using the same method. For 10X Genome, aligned fragment positions and metadata were obtained from the 10X Genome website. Abbreviations used throughout the plots: bu, Buenrostro et al., Nature 523 (2015) Fluidigm C1 ATAC-seq; cu, Cusanovich et al., Science 348 (2015) sci-ATAC-seq (2015); gr, Graybuck et al. (data presented herein) FACS scATAC-seq; pl, Pliner et al., Mol. Cell 71 (2018) sci-ATAC-seq (2018); and tx, 10X Genomics, 5k cell 10X ATAC-seq. Gray et al., Elife 1-30 (2017). Dual-axis QC criteria plot showing the QC1 and QC2 cutoffs used for mouse cortical scATAC-seq data. [Figure 44]Gm12878 platform comparison. Aggregate fragment length frequency plots. Fragment length is shown on the x-axis, and the fraction of reads with fragments of each bp size was calculated for each sample within each dataset. For this analysis, the median fraction at each fragment size is shown as a solid line, and the 25th and 75th percentiles are shown in the shaded areas. Abbreviations used throughout the plots: bu, Buenrostro et al., Nature 523 (2015) Fluidigm C1 ATAC-seq; cu, Cusanovich et al., Science 348 (2015) sci-ATAC-seq (2015); gr, Graybuck et al. (data described herein). [Figure 45] Samples were clustered in t-SNE space using a phenograph implementation of Louvain clustering. To identify cell types within these clusters, cells from each cluster were pooled and the number of fragments within 20 kb of each TSS was counted. Marker genes for transcriptome clusters were then selected from Tasic et al., Nature 563, 72-78 (2018), and TSS accessibility scores were correlated with log-transformed gene expression. The scRNA-seq cluster with the highest correlation score was assigned as the identity of each phenotype cluster, and clusters with the same transcriptome mapping were combined for downstream analysis. The cluster with the highest correlation score was assigned as the identity of each cluster, and clusters with the same transcriptome mapping were combined for downstream analysis. [Figure 46A]scATAC-seq data. Dot plots show both the fraction of cells in each subclass expressing each gene (dot size) and the median expression level within each subclass (dot color). scATAC-seq data were grouped by subclass based on transcriptomic mapping, and after fragment count normalization, aggregated fragment overlaps near the gene of interest were plotted (track plot, right panel). Subclass-level gene expression profiles (dot plot, left panel) derived from Tasic et al. (2018, Nature) demonstrate highly specific expression of the Fam84b gene in the L5 PT subclass. Fam84b (family with sequence similarity 74, member B) is a transcription factor gene recently shown to be a highly selective marker gene for L5 PT neurons across two regions of the mouse cortex (Tasic et al. (2018) Nature). A peak of accessibility specific to L5 PT samples (mscRE4) was identified 113 kb downstream from the Fam84b TSS. [Figure 46B]scATAC-seq data. Dot plots show both the fraction of cells in each subclass expressing each gene (dot size) and the median expression level within each subclass (dot color). scATAC-seq data were grouped by subclass based on transcriptomic mapping, and after fragment count normalization, aggregated fragment overlaps near genes of interest were plotted (track plot, right panel). Subclass-level gene expression profiles (dot plot, left panel) from Tasic et al. (2018) show enrichment of Hsd11b1 expression in L5 IT and L5 PT cell types. Hsd11b1 (hydroxysteroid 11-beta dehydrogenase 1) is a gene involved in corticosteroid biosynthesis. It has been shown to be selectively expressed in L5 cells, with higher expression in some L5 IT types than in L5 PT cells (Tasic et al. (2018) Nature). A peak of accessibility enriched in L5 IT cells but absent in L5 PT cells (mscRE16) was identified 34 kb upstream of the Hsd11b1 TSS. The cell types listed along the sides of Figures 46A and 46B are Lamp5, Sncg, Serpinf1, Vip, Sst Pvalb, L2 / 3 IT, L4, L5 IT, L6 IT, L5 PT, NP, L6 CT, L6b, Meis2, and CR. [Figure 46C] scATAC-seq data. Dot plots show both the fraction of cells in each subclass expressing each gene (dot size) and the median expression level within each subclass (dot color). scATAC-seq data were grouped by subclass based on transcriptomic mapping, and after fragment count normalization, aggregated fragment overlaps near genes of interest were plotted (track plot, right panel). scATAC-seq data showed a peak in accessibility specific to mscRE10, located 34 kb upstream of Car3. [Figure 46D]scATAC-seq data. Dot plots show both the fraction of cells in each subclass that express each gene (dot size) and the median expression level within each subclass (dot color). The scATAC-seq data were grouped by subclass based on transcriptomic mapping, and after fragment count normalization, aggregated fragment overlaps near the gene of interest were plotted (track plot, right panel). (D) The scATAC-seq data showed a peak in accessibility specific to mscRE13, located 86 kb upstream of Osr1. [Figure 47] mscRE location and cloning primers. [Figure 48] (A) Direct enhancer-driven expression of fluorophores was tested by cloning the putative mscRE4 or mscRE16 enhancer in scAAV constructs with a minimal promoter driving the fluorophore WPRE3. After packaging, purified, and titrated scAAV was injected retro-orbitally into wild-type mice. (B) Two weeks after retro-orbital injection of rAAV carrying mscRE16 driving expression of EGFP (TG1002), cells were selectively labeled in L5 of the mouse cortex by EGFP expression, which is amplified here using antibody staining by immunohistochemistry (IHC). (C) Two weeks after retro-orbital injection of scAAV carrying mscRE4 driving expression of SYFP (T502-057), dim but distinct labeling of L5 PT cells was observed by native fluorescence without antibody amplification. [Figure 49A] Validation of cell type targeting of the scAAV-mscRE4-SYFP2 virus by scRNA-seq. Enhancer-driven recombinase expression was tested using a scAAV construct with a minimal promoter driving EGFP-WPRE3. After packaging, mice were injected retro-orbitally. After two weeks, SYFP-expressing cells were visible in the cortex, which could be isolated by FACS and used for scRNA-seq. [Figure 49B]Validation of cell type targeting of scAAV-mscRE4-SYFP2 virus by scRNA-seq. Centroid classifier mapping of labeled cells to data from Tasic et al. (2018, Nature) revealed that 91.8% of cells mapped to the L5 PT transcriptome cell type. [Figure 50A] Electrophysiological characterization of mscRE4-labeled cells and demonstration of its utility for electrophysiological recording of labeled neurons. Cortical slices from animals labeled with the scAAV-mscRE4-SYPF2 (T502-057) virus were used for electrophysiological characterization. Example impedance amplitude profiles obtained from (yellow fluorescent protein) YFP+ and YFP- neurons in the VISp. For comparison, impedance amplitude profiles from unlabeled PT-like and IT-like neurons from the somatosensory cortex are also shown. Resonance frequency is plotted as a function of input resistance. [Figure 50B] Electrophysiological characterization of mscRE4-labeled cells and demonstration of its utility for electrophysiological recording of labeled neurons. Example voltage responses to a series of hyperpolarizing and depolarizing current injections of YFP+ and YFP- neurons. For reference, exemplary voltage responses obtained from unlabeled PT-like and IT-like neurons are also shown. [Figure 50C] Electrophysiological characterization of mscRE4 labeled cells and demonstration of the utility for electrophysiological recording of labeled neurons. Input resistance, perpendicular ratio, and resonant frequency for three experimental conditions. [Figure 51] Additional electrophysiological characteristics of mscRE4-SYFP2-labeled cells. (A) Microscopy of example cells characterized by patch electrophysiology. On the left, a SYFP2-positive cell; on the right, a SFYP2-negative cell. (B) Input resistance, perpendicular ratio, and resonant frequency for four experimental conditions: IT, YFP-, YFP+, and PT. [Figure 52]Stereotaxic labeling using enhancer-driven viruses. (A) Native fluorescence image of an animal with stereotaxic injection of mscRE4-EGFP in the primary visual cortex. The enhancer-driven virus was co-injected with the constitutive dTomato virus, rAAVDJ-EF1a-dTomato, at 0.1x the volume of the mscRE virus to provide the location of the injection site (dotted outline). (B) Native fluorescence image of an animal with stereotaxic injection of mscRE4-SYFP2 into the primary visual cortex at the volume indicated. [Figure 53] Several enhancer-driven recombinase viruses provide specific binary labeling. Three different recombinases and one transactivator were inserted downstream of the mscRE4 and promoter in the viral construct. After retroorbital injection, labeling of L5 was observed with varying degrees of specificity using tTA2 (TG1011, SEQ ID NO: 88) in Ai63 reporter mice (rarest, most specific), FlpO (TG978, SEQ ID NO: 80) in Ai65F reporter mice (most complete and specific), iCre (TG1010, SEQ ID NO: 87) in Ai14 reporter mice (complete, but with L6 background), and dgCre in Ai14 reporter mice (least specific). Images show spontaneous fluorescence in the visual cortex 2 weeks after injection. For illustrations, see Figures 68A-G. [Figure 54-1] Whole-brain imaging of retro-orbitally delivered mscRE4-FlpO-WPRE3 (TG978, SEQ ID NO: 80) viral labeling reveals specific L5-restricted labeling throughout the cortex, as well as labeling of specific subcortical populations in the central amygdala nucleus, part of the CeA, the pars saccularis (CEAc) that receives and processes pain signals; the substantia nigra pars compacta (or pars compacta, SNc), involved in movement control and affected in Parkinson's disease; and the prosbiculum (ProS). [Figure 54-2]Whole-brain imaging of retro-orbitally delivered mscRE4-FlpO-WPRE3 (TG978, SEQ ID NO: 80) viral labeling reveals specific L5-restricted labeling throughout the cortex, as well as labeling of specific subcortical populations in the central amygdala nucleus, part of the CeA, the pars saccularis (CEAc) that receives and processes pain signals; the substantia nigra pars compacta (or pars compacta, SNc), involved in movement control and affected in Parkinson's disease; and the prosbiculum (ProS). [Figure 55] Validation of cell type targeting of the mscRE4-FlpO-WPRE3 virus by scRNA-seq. (A) Enhancer-driven recombinase expression was tested using an rAAV construct with a minimal promoter driving FlpO-WPRE3. After packaging, Ai65F mice were injected retro-orbitally. Two weeks later, tdTomato-expressing cells became visible in the cortex, which could be isolated from L5 dissociations, sorted by FACS, and used for scRNA-seq. (B) Centroid classifier mapping of labeled cells to data from Tasic, et al. (2018, Nature) revealed that 90.6% of cells mapped to L5 PT transcriptome cell types. The list of cell types along the right, from top to bottom, is as follows: Sst Hpse Cbln4(3), L5 IT VISp Hsd11b1 Endou(2), L5 PT VISp Chrna6(2), L5 PT VISp Lgr5(2), L5 PT VISp C1ql2 Ptgfr(40), L5 PT VISp C1ql2 Cdh13(40), and L5 PT VISp Krt80(7). [Figure 56A]Dual-labeling and titration of viral copy number to achieve high-titer, broad-spectrum labeling. These experiments were performed by retro-orbital co-injection of mscRE4-FLPO (TG978, SEQ ID NO: 80) and mscRE16-EGFP (TG1002, SEQ ID NO: 86) viruses into FLP-dependent tdTOMATO reporter mice (Ai65F). See Figure 68 for a depiction of this dual-labeling strategy. Corners of the fluorescent images identify the fluorophores (anti-GFP, native tdTomato, and integration). [Figure 56B] Dual-labeling and titration of viral copy number to achieve high-titer, broad-spectrum labeling. These experiments were performed by retro-orbital co-injection of mscRE4-FLPO (TG978, SEQ ID NO: 80) and mscRE16-EGFP (TG1002, SEQ ID NO: 86) viruses into FLP-dependent tdTOMATO reporter mice (Ai65F). See Figure 68 for a depiction of this dual-labeling strategy. Corners of the fluorescent images identify the fluorophores (anti-GFP, native tdTomato, and integration). [Figure 56C] Dual-labeling and titration of viral copy number to achieve specific, exclusive labeling at low titers. These experiments were performed by retro-orbital co-injection of mscRE4-FLPO (TG978, SEQ ID NO: 80) and mscRE16-EGFP (TG1002, SEQ ID NO: 86) viruses into FLP-dependent tdTOMATO reporter mice (Ai65F). See Figure 68 for a depiction of this dual-labeling strategy. Corners of the fluorescent images identify the fluorophores (anti-GFP, native tdTomato, and integration). [Figure 57A]Enhancer-driven recombinase virus as a driver for cell labeling. Whole-section images of mscRE4-FlpO injections show labeling throughout L5 of the posterior cortex. The inset region on the right corresponds to the white box on the left. Layer overlay from the Allen Brain Reference Atlas shows that labeling is restricted to L5. tdTomato+ cells were dissected from all cortical depths and collected by FACS for scRNA-seq. Transcriptomic profiles were mapped to reference cell types from Tasic et al. (2018). 87.5% (28 of 32) of cells mapped to the L5 PT cell type. [Figure 57B] Enhancer-driven recombinase virus as a driver for cell labeling. Full-section images of mscRE10-FlpO injections show labeling in layer 6 (L6) of the cortex. The inset on the right corresponds to the white box on the left. scRNA-seq of tdTomato+ cells shows that layer 6 corticothalamic (L6 CT) and L6b cell types are the most frequently labeled neuronal subclasses at 75% (n = 36 of 48). [Figure 57C] Enhancer-driven recombinase virus as a driver for cell labeling. Full-section images of mscRE16-FlpO injections show labeling in L5 of the cortex. The inset on the right corresponds to the white box on the left. scRNA-seq of tdTomato+ cells shows that the L5 IT cell type is the most frequently labeled neuronal subclass at 42% (n=20 of 48), although other subclasses are also labeled at this titer (Lamp5, 27%; L6 IT, 6%; L5 PT, 15%). [Figure 58]Retroorbital mscRE driver screening at multiple titers. Native fluorescence images of reporter mice injected retroorbitally (RO) with enhancer-driven recombinase virus at two titers: low RO, 1 x 10 genome copies, GC; high RO, 1 x 10 GC. Fluorescence is tdTomato. The scale bar size can be determined using the Scale Bar Key, where triangles indicate a 100 μm scale, seven-point stars indicate a 500 μm scale, and five-point stars indicate a 1000 μm scale. Arrows indicate where the layers are labeled; the direction of the arrow indicates where the layers are labeled: L1, L2 / 3, L4, L5, L6, and L6b. [Figure 59A] Whole-brain and cross-labeling of cell types. Results of whole-brain imaging using TissueCyte. Whole-brain sections from Ai65F mice after retro-orbital injection of MscRE-FlpO were aligned to the Allen Institute Common Coordinate Framework (CCF) and mapped to the Allen Brain Atlas structural ontology. A high-level overview of cellular labeling across the structural ontology is presented by a classification plot. "Grey" is the root of the plot, representing all gray matter regions, and each branch of the node indicates a child structure within each region. The size and color of the node represent the maximum signal found among all children of the node, allowing one to follow the tree to sources of high signal within each structure. Inserts display selected regions of high or specific signal. Region initials correspond to the Allen Brain Adult Mouse Atlas. [Figure 59B]Whole-brain and cross-labeling of cell types. Further division of isocortical regions in the TissueCyte dataset down to the level of cortical layers allows for brain-wide quantification of layer-specific signal. A representative cortical section from the TissueCyte dataset is shown at the top along from most anterior to most posterior (left to right). Heatmaps show quantification of signal in each region and layer. Agranular regions lacking layer 4 have a hash in the L4 column. The front and rear regions are FRP, ORBv1, ORBm, ORBI, PL, ILA, Aid, Mos, Alv, Mop, SSp-m, GU, ACAd, SSp-n, SSp-un, ACAv, SSp-uI, SSp-II, VISC , Aip, SSs, SSp-bfd, SSp-tr, AUDv, AUDd, AUDp, PTLp, RSPv, RSPd, PERI, VISam, TE, ECT, AUDpo, VISI, VISpm, and VISpI. [Figure 59C] Whole-brain and cross-labeling of cell types. Diagram showing the use of coinjected recombinase viruses in a dual-reporter system for co- or cross-labeling of cell types. In this experiment, one virus driving FlpO and a second virus driving iCre are co-injected into mice along with genetically encoded Flp- and Cre-dependent reporters. In the target cell type, enhancers drive recombinases, permanently labeling that target cell type. If the selected enhancers are mutually exclusive, different populations will be labeled. If they overlap, cross-labeling is possible. [Figure 59D] Whole-brain and cross-labeling of cell types. Native fluorescence images of Ai65F, Ai140 dual reporter mouse strains injected retro-orbitally with mscRE16-FlpO (red fluorescence) and mscRE4-iCre (green fluorescence). These enhancers are expected to label mutually exclusive cell types in L5 of the cortex. The white boxed area corresponds to the inset image, showing strong labeling of the L5 strain. [Figure 59E]Whole-brain and cross-labeling of cell types. Number of cells in each layer for all cortical regions labeled with EGFP (mscRE4; L5 PT), tdTomato (mscre16; L5 IT), or both in the image in (Figure 59D). [Figure 60A] Whole-brain characterization of mscRE16-FlpO. TissueCyte images of mscRE16-FlpO, Ai65F mice 2 weeks after retro-orbital injection, were registered in the Allen Institute Common Coordinate Framework (CCF), and each structure was scored on an adult mouse structure. Figures 59A-59E show a high-level overview of cellular labeling across the structural ontology. Node size and color represent the maximum signal found among all children of the node, allowing us to follow the tree to the source of high signal within each structure. Insets display selected regions of high or specific signal. The lower left inset shows the projection of IT neurons across the corpus callosum. [Figure 60B] Whole-brain characterization of mscRE16-FlpO. Layer quantification on the same TissueCyte image registered to CCF for all isocortical regions. Agranular regions lacking L4 are indicated by white boxes in the L4 row. All acronyms correspond to the Allen Institute for Brain Science adult mouse 3D atlas. [Figure 61A] mscRE4 AAV vectors target rare L5 PT neurons in the human cortex. Human acute slice cultures dissected from the middle temporal gyrus (MTG) were infected with a quadruplet virus: two mscRE4-driven rAAVs expressing Cre or Flp recombinase, and two fluorescent reporter viruses, one expressing SYFP and the other expressing RFP. This strategy allows for high specificity by selecting only co-labeled neurons. Biocytin loading of co-labeled cells used for patch electrophysiology reveals a morphology consistent with human L5 PT neurons. [Figure 61B]mscRE4 AAV vectors targeting rare L5 PT neurons in the human cortex. Human acute slice cultures dissected from the middle temporal gyrus (MTG) were infected with a quadruplet virus: two mscRE4-driven rAAVs expressing Cre or Flp recombinase, and two fluorescent reporter viruses, one expressing SYFP and the other expressing RFP. This strategy allows for high specificity by selecting only co-labeled neurons. Double fluorescent labeling of L5 PT neurons in the human cortex (scale bar 100 microns). [Figure 61C] mscRE4 AAV vectors target rare L5 PT neurons in the human cortex. Human acute slice cultures dissected from the middle temporal gyrus (MTG) were infected with a quadruplet virus: two mscRE4-driven rAAVs expressing Cre or Flp recombinase, and two fluorescent reporter viruses, one expressing SYFP and the other expressing RFP. This strategy allows for high specificity by selecting only co-labeled neurons. Transcript validation was performed by mapping RNA extracted from labeled cells using patch sequencing. RNA was reverse transcribed, amplified, sequenced, and mapped to a human MTG reference dataset. A bootstrapped centroid classifier was used to match human L4 / 5 PT cell types in 100 out of 100 trials. [Figure 61D] mscRE4 AAV vectors target rare L5 PT neurons in the human cortex. Human acute slice cultures dissected from the middle temporal gyrus (MTG) were infected with a quadruplet virus: two mscRE4-driven rAAVs expressing Cre or Flp recombinase, and two fluorescent reporter viruses, one expressing SYFP and the other expressing RFP. This strategy allows for high specificity by selecting only co-labeled neurons. The electrophysiological properties of co-labeled human L5 PT cells were consistent with previous studies of L5 PT cells, demonstrating the utility of this method for selective electrophysiological targeting. [Figure 62-1] Annotated sequence of CN1818 [Figure 62-2] Annotated sequence of CN1818 [Figure 62-3] Annotated sequence of CN1818 [Figure 62-4] Annotated sequence of CN1818 [Figure 62-5] Annotated sequence of CN1818 [Figure 62-6] Annotated sequence of CN1818 [Figure 63] 3xCore-mscRE4-SYFP2 virus (CN1818, SEQ ID NO: 109) was injected retro-orbitally into adult mice. Three weeks after injection, brains from the injected mice were sectioned and imaged to assess target expression of the SYFP2 fluorophore label. Strong expression of the SYFP2 reporter gene in adult mouse brains was observed after retro-orbital injection of CN1818. Labeled cells were primarily located in layer 5 and had electrophysiological properties consistent with L5 PT neurons. [Figure 64] (A) Nissl staining of the M1 region in a macaque brain slice showing neocortical layers and a higher magnification view of the boxed area showing numerous magnopyramidal Betz cells (white arrows). (B) Native YFP expression detected in Betz cells (white arrows) 4 days after infection with CN1818 and the corresponding Nissl staining of the same field. [Figure 65] (A) Expected viral labeling (green) and targeted patch-clamp recording of a putative Betz cell in a cultured macaque M1 brain slice infected with CN1818 using Alexa dye filling (red) from a patch pipette. (B) Firing in response to a 1 s, 3 nA current injection step, showing a narrow action potential width. (C) Summary plot showing high firing rates in response to escalating current injection steps. [Figure 66A] Spike frequency acceleration and subthreshold membrane potential oscillations in the gamma band shown for CN1818 virally labeled macaque M1 putative Betz cells. [Figure 66B] Significant high speed sag, low input resistance (19MOhms). [Figure 66C] Subthreshold membrane resonance with a peak resonant frequency of 5.3 Hz. [Figure 67] The 3xCore-mscRE4-SYFP2 virus (CN1818, SEQ ID NO: 109) was applied to human surgical ex vivo cortical slice cultures. After incubation, the cortical slices were imaged under a microscope to assess target expression of the SYFP2 fluorophore label. CN1818 was found to label L5 PT neurons in human ex vivo neocortical brain slice cultures. The scale bar is 1 mm long. [Figure 68A] Figure 1 shows a conventional Cre / lox system for generating cell type-specific markers by breeding. [Figure 68B] 1 shows the conventional Flp / FRT system for generating cell type-specific labeling by breeding. [Figure 68C] 1 shows a conventional TET transactivator / TET responsive element (tTA2 / TRE) system used to generate cell type-specific labeling. [Figure 68D] We demonstrate a mechanism for bypassing propagation by replacing the viral Cre driver. [Figure 68E] This shows the mechanism by which propagation is bypassed by replacing the viral Flp driver. [Figure 68F] We demonstrate a mechanism for bypassing propagation by replacing the viral tTA driver and demonstrate an additional layer of regulation via doxycycline treatment, which can reduce or inactivate tTA2 activity. [Figure 68G] We demonstrate bypassing these systems entirely for direct labeling. A strong advantage of Cre- or Flp-dependent reporters is that they can be much brighter and are permanently turned on after recombination, removing the stop site. The tTA2 / TRE system is an additional mechanism for selective labeling that can be tunable by doxycycline treatment. [Figure 69]Diagrammatic overview of a multiviral labeling system. Here, two different viruses, driven by the same or different enhancers, drive either a recombinase or a fluorophore. Upon injection into reporter mice, the enhancer-driven recombinase triggers excision of a termination site in a target cell type, while the enhancer-driven fluorophore is directly expressed in another target cell type. If these cell types overlap in their use of viral enhancer elements, cross-reactive co-labeling can be observed. [Figure 70] Enhancer ID, labeled cell type, and validation method. [Figure 71-1] Summary of Vector Components: Sequence names, relative lengths, enhancers, promoters, product classes, primary products, and other components of the expression constructs described herein. [Figure 71-2] Summary of Vector Components: Sequence names, relative lengths, enhancers, promoters, product classes, primary products, and other components of the expression constructs described herein. [Figure 71-3] Summary of Vector Components: Sequence names, relative lengths, enhancers, promoters, product classes, primary products, and other components of the expression constructs described herein. [Figure 72-1] Classification and clustering of selected central nervous system cells. [Figure 72-2] Classification and clustering of selected central nervous system cells. [Figure 72-3] Classification and clustering of selected central nervous system cells. [Figure 72-4] Classification and clustering of selected central nervous system cells. [Figure 73A] Enhancer targeting validation data. FM stands for fluorescence microscope. [Figure 73B-1] Cell type specificity of the enhancers and vectors described herein. S = subset of types within a group; A = all types within a group; * = validated in mouse, RNA-seq, and a third modality; ~ = validated in mouse, RNA-seq, primate / human, and a fourth modality. [Figure 73B-2]Cell type specificity of the enhancers and vectors described herein. S = subset of types within a group; A = all types within a group; * = validated in mouse, RNA-seq, and a third modality; ~ = validated in mouse, RNA-seq, primate / human, and a fourth modality. [Figure 73B-3] Cell type specificity of the enhancers and vectors described herein. S = subset of types within a group; A = all types within a group; * = validated in mouse, RNA-seq, and a third modality; ~ = validated in mouse, RNA-seq, primate / human, and a fourth modality. [Figure 73B-4] Cell type specificity of the enhancers and vectors described herein. S = subset of types within a group; A = all types within a group; * = validated in mouse, RNA-seq, and a third modality; ~ = validated in mouse, RNA-seq, primate / human, and a fourth modality. [Figure 74] 1 is a schematic diagram of cortical layers with particular relevance to the primate visual cortex. This schematic is provided as an illustration of intracortical layers. [Figure 75] Database of human neocortical cell subclass-specific accessible chromatin elements. [A] (A) Workflow for human neocortex epigenetic characterization. [B] High-quality nuclei (2858 from 14 specimens) visualized by tSNE and colored according to cell type (B), sorting strategy (C), or specimen (D) for the mapped transcriptome. (E) Transcriptomic abundance of 11 known cell subclass-specific marker genes across 75 cell types identified in the middle temporal gyrus of the human temporal cortex (Hodge et al., bioRxiv, 384826, 2018). [Figure 76]Mapping ATAC-seq clusters to RNA-seq cell types. Transcriptome cell types within a subclass were summed for cluster-wise mapping to obtain cluster-wise mapping to subclasses. This plot shows the final mapped subclass assigned as the most frequent mapping for each cluster, and these subclass identities are used for the pileup and calculations in Figures 75B, 77, and 78. [Figure 77] Characterization of human neocortical cell subclass-specific accessible genomic elements. Comparing actual peak and randomized peak locations, overlap rates between ATAC-seq peaks and previously identified DMRs (Lister et al., Science. 341, 1237905, 2013; Luo et al., Science. 357, 600-604, 2017). Absolute numbers of detected peaks and peak-DMR overlaps are shown. [Figure 78] Accessible chromatin elements provide human genetic tools. Multiple enhancer-AAV vectors confer distinct subclass selectivity. Seven loci and ATAC-seq read pileups, as well as expression patterns in mouse V1 for the seven AAV reporter vectors, are shown. Scale 200 μm. [Figure 79-1]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-2]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-3]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-4]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-5]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-6]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-7]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-8]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-9]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-10]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-11]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-12]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-13]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-14]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-15]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-16]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-17]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-18]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-19]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-20]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-21]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-22]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-23]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-24]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Fig. 79-25]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-26]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-27]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-28]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-29]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-30]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-31]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Fig. 79-32]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ ID NO: 25), Enhancer mscRE1 (eAi1.0) (SEQ ID NO: 26), Enhancer mscRE3 (eAi2.0) (SEQ ID NO: 27), Enhancer mscRE4 (eAi3.0) (SEQ ID NO: 28), Enhancer mscRE4 core (SEQ ID NO: 29), Enhancer 3xmscRE4 core (eAi3.2) (SEQ ID NO: 30), enhancer mscRE4 (4x) (eAi3.1) (SEQ ID NO: 31), enhancer mscRE10 (eAi6.0) (SEQ ID NO: 32), enhancer mscRE11 (eAi7.0) (SEQ ID NO: 33), enhancer mscRE12 long form (SEQ ID NO: 34), enhancer mscre12 (eAi8.0) (SEQ ID NO: 35), enhancer mscRE13 (eAi9.0) (SEQ ID NO: 36), enhancer mscRE16 (eAi11.0) (SEQ ID NO: 37), enhancer 4XmscRE16 (eAi11.1) (SEQ ID NO: 38), enhancer eHGT_078h (eAi107.0) (SEQ ID NO: 39), enhancer eHGT_078h core (SEQ ID NO: 177), Enhancer eHGT_078h (3xCore) (eAi129.0) (SEQ ID NO: 40), enhancer eHGT_058h (eAi106.0) (SEQ ID NO: 41), enhancer eHGT_058m (eAi108.0) (SEQ ID NO: 42), enhancer eHGT_073h (eAi111.0) (SEQ ID NO: 43), enhancer eHGT_073m (eAi1 12.0) (SEQ ID NO: 44), enhancer eHGT_075h (eAi113.0) (SEQ ID NO: 45), enhancer HGT_077h (eAi114.0) (SEQ ID NO: 46), enhancer eHGT_254h (eAi127.0) (SEQ ID NO: 47), enhancer eHGT_078m (eAi128.0) (SEQ ID NO: 48), enhancer eHGT_078m Core (SEQ ID NO: 178), enhancer eHGT_078m (3xCore) (eAi130.0) (SEQ ID NO: 49), enhancer eHGT_439m (eAi131.0) (SEQ ID NO: 50), enhancer eHGT_440h (eAi132.0) (SEQ ID NO: 51),Beta globin minimal promoter (SEQ ID NO: 52), minCMV (SEQ ID NO: 53), mutated minCMV promoter (SEQ ID NO: 54), Hsp68 minimal promoter (SEQ ID NO: 55), SYFP2 (SEQ ID NO: 56), EGFP (SEQ ID NO: 57), optimized Flp recombinase (SEQ ID NO: 58), improved Cre recombinase (SEQ ID NO: 59), WPRE3 (SEQ ID NO: 60), BGHpA (SEQ ID NO: 61), HA tag (SEQ ID NO: 62), HA tag (SEQ ID NO: 63), P2A (SEQ ID NO: 64), T2A (SEQ ID NO: 65), E2A (SEQ ID NO: 66), F2A (SEQ ID NO: 67), tet-transactivator (SEQ ID NO: 68), PHP.eB capsid (SEQ ID NO: 69), AAV9 VP1 capsid (SEQ ID NO: 70), plasmid backbone 1 (SEQ ID NO: 71), plasmid backbone 2 (SEQ ID NO: 72), T502-050 (vAi33.0) (SEQ ID NO: 73), T502-054 (vAi33.1) (SEQ ID NO: 179), T502-057 (vAi3.0) (SEQ ID NO: 74), T502-059 (vAi2.0) (SEQ ID NO: 75), vAi1.0 (SEQ ID NO: 76), vAi3 3.2 (TG1114) (SEQ ID NO: 77), vAi34.0 (TG1108) (SEQ ID NO: 78), vAi45.0 (TG1109) (SEQ ID NO: 79), TG975 (vAi4.0) (SEQ ID NO: 180), TG978 (vAi4.1) (SEQ ID NO: 80), TG979 (vAi4.2) (SEQ ID NO: 181), TG981 (vAi5.0) (SEQ ID NO: 81), TG982 (vAi6.0) ( SEQ ID NO: 182), TG987 (vAi7.0) (SEQ ID NO: 183), TG988 (vAi7.1) (SEQ ID NO: 82), TG995 (vAi15.0) (SEQ ID NO: 83), TG996 (vAi19.0) (SEQ ID NO: 84), TG997 (vAi20.0) (SEQ ID NO: 184), TG999 (vAi21.0) (SEQ ID NO: 85), TG1002 (vAi26.0) (SEQ ID NO: 86), T G1009 (vAi8.0dgCre) (SEQ ID NO: 185), TG1010 (vAi6.1) (SEQ ID NO: 87), TG1011 (vAi7.2) (SEQ ID NO: 88), TG1021 (vAi8.0Cre) (SEQ ID NO: 89), TG1022 (vAi9.0) (SEQ ID NO: 186), TG1036 (vAi16.0) (SEQ ID NO: 90), TG1037 (vAi22.0) (SEQ ID NO: 91),TG1038 (vAi27.0) (SEQ ID NO: 92), TG1045 (vAi17.0) (SEQ ID NO: 187), TG1046 (vAi23.0) (SEQ ID NO: 93), TG1047 (vAi28.0) (SEQ ID NO: 94), TG1048 (vAi18.0) (SEQ ID NO: 95), TG1049 (vAi24.0) (SEQ ID NO: 96), TG1050 (vAi29.0) (SEQ ID NO: 97), TG1052 (vAi10.0) (SEQ ID NO: 98), CN1402 (vAi106.0) (SEQ ID NO: 99), CN1416 (vAi108.0) (SEQ ID NO: 100), CN142 7 (vAi130.0) (SEQ ID NO: 101), CN1452 (vAi111.0) (SEQ ID NO: 102), CN1454 (vAi113.0) (SEQ ID NO: 103), CN1456 (vAi114.0) (SEQ ID NO: 104), CN1457 (vAi107.0) (SEQ ID NO: 105), CN1461 (vAi112.0) (SEQ ID NO: 106), CN1466 (vAi131.0) (SEQ ID NO: 107), CN1772 (vAi127.0) (SEQ ID NO: 108), CN1818 (vAi128.0) (SEQ ID NO: 109), CN1954 (vAi132.0) (SEQ ID NO: 110), CN1955 (vAi133.0) (SEQ ID NO: 111), CN2014 (vAi129.0) (SEQ ID NO: 112), CN2137 (vAi135.0) (SEQ ID NO: 113), CN2139 (vAi134.0) (SEQ ID NO: 114), myosin light chain kinase, green fluorescent protein, calmodulin chimera (SEQ ID NO: 115), genetically encoded green calcium indicator NTnC (SEQ ID NO: 116), calcium indicator TN-XXL (SEQ ID NO: 117), BRET-type autoluminescent calcium indicator (SEQ ID NO: 118), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 119), GCaMP6m (SEQ ID NO: 120), GCaMP6s (SEQ ID NO: 121), GCaMP6f (SEQ ID NO: 122), channelrhodopsin-1 (SEQ ID NOs: 123 and 124), channelrhodopsin-2 (SEQ ID NOs: 125 and 126), CRISPR-associated protein (Cas) (SEQ ID NO: 127), Cas9 (SEQ ID NO: 128), CRISPR-associated endonuclease Cpf1 (SEQ ID NO: 129), ribonuclease 4 or ribonuclease L (SEQ ID NO: 130),Deoxyribonuclease II beta (SEQ ID NO: 131), sodium channel protein type 1 subunit alpha (SEQ ID NO: 132), voltage-gated potassium channel subfamily KQT member 2 (SEQ ID NO: 133), voltage-gated L-type calcium channel subunit alpha-1C (SEQ ID NO: 134), lactase (SEQ ID NO: 135), lipase (SEQ ID NO: 136), helicase (SEQ ID NO: 137), amylase (SEQ ID NO: 138), alpha glucosidase (SEQ ID NO: 139), transcription factor SP1 (SEQ ID NO: 140), Transcription factor AP-1 (SEQ ID NO: 141), heat shock protein 1 (SEQ ID NO: 142), CCAAT / enhancer binding protein (C / EBP) beta isoform a (SEQ ID NO: 143), octamer binding protein 1 (Oct-1) (SEQ ID NO: 144), transforming growth factor beta 1 (SEQ ID NO: 145), platelet-derived growth factor receptor (SEQ ID NO: 146), epidermal growth factor receptor (SEQ ID NO: 147), vascular endothelial growth factor (SEQ ID NO: 148), interleukin-8 receptor alpha (SEQ ID NO: 149), caveolin ( SEQ ID NO: 150), dynamin (SEQ ID NO: 151), clathrin heavy chain 1 isoform 1 (SEQ ID NO: 152), clathrin heavy chain 2 isoform 1 (SEQ ID NO: 153), clathrin light chain A isoform a (SEQ ID NO: 154), clathrin light chain B isoform a (SEQ ID NO: 155), Ras-related protein Rab-4A isoform 1 (SEQ ID NO: 156), Ras-related protein Rab-11A (SEQ ID NO: 157), platelet-derived growth factor (SEQ ID NO: 158), transforming growth factor beta 3 (SEQ ID NO: 159), neurotrophic factor agonist (NDA) (SEQ ID NO: 160), neurotrophic factor agonist (NDA) (SEQ ID NO: 161), neurotrophic factor agonist (NDA) (SEQ ID NO: 162), neurotrophic factor agonist (NDA) (SEQ ID NO: 163), neurotrophic factor agonist (NDA) (SEQ ID NO: 164), neurotrophic factor agonist (NDA) (SEQ ID NO: 165), neurotrophic factor agonist (NDA) (SEQ ID NO: 166), neurotrophic factor agonist (NDA) (SEQ ID NO: 167), neurotrophic factor agonist (NDA) (SEQ ID NO: 168), neurotrophic factor agonist (NDA) (SEQ ID NO: 169), neurotrophic factor agonist (NDA) (SEQ ID NO: 170), neurotrophic factor agonist (NDA) (SEQ ID NO: 171), neurotrophic factor agonist (NDA) (SEQ ID NO: 172), neurotrophic factor agonist (NDA) (SEQ ID NO: 173), neurotroph Growth factor (SEQ ID NO: 160), epidermal growth factor (EGF) (SEQ ID NO: 161), GTPase HRas (SEQ ID NO: 162), cocaine- and amphetamine-regulated transcript (chain A) (SEQ ID NO: 163), protachykinin-1 (SEQ ID NO: 164), substance P is at positions 58-68 of protachykinin-1 (SEQ ID NO: 165), oxytocin-neurophysin-1 (SEQ ID NO: 166), oxytocin is at positions 20-28 of oxytocin-neurophysin-1 (SEQ ID NO: 167), and somatostatin (SEQ ID NO: 168). The nucleic acid sequences described herein are intended to be representative of the sequences of:The sequences are shown using standard letter abbreviations for nucleotide bases. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in embodiments where appropriate. [Figure 79-33]Sequences supporting the present disclosure. Enhancer Grik1-enhScnn1a-1 short form (SEQ ID NO: 188), Enhancer Grik1-enhScnn1a-1 (eAi14.0) (SEQ...

Claims

1. A nucleic acid comprising an artificial enhancer sequence, wherein the artificial enhancer sequence is The sequence shown in sequence number 28, The sequence shown in sequence number 29, The sequence shown in sequence number 37, A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 28, and having the same enhancer activity as the sequence shown in Sequence ID No. 28, A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 29, and having the same enhancer activity as the sequence shown in Sequence ID No. 29, or A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 37, and having the same enhancer activity as the sequence shown in Sequence ID No.

37. Nucleic acids, including

2. The artificial enhancer sequence is Three copies of the sequence shown in Sequence ID No. 29, or Three copies of a sequence that has at least 95% sequence identity with the sequence shown in Sequence ID No. 29 and has the same enhancer activity as the sequence shown in Sequence ID No.

29. The nucleic acid according to claim 1, having the following characteristics.

3. The artificial enhancer sequence is Four copies of the sequence shown in sequence number 29, Four copies of the sequence shown in sequence number 37, Four copies of a sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 29, and having the same enhancer activity as the sequence shown in Sequence ID No. 29, or Four copies of a sequence that has at least 95% sequence identity with the sequence shown in Sequence ID No. 37 and has the same enhancer activity as the sequence shown in Sequence ID No.

37. The nucleic acid according to claim 1, having the following characteristics.

4. The artificial enhancer sequence is The sequence shown in sequence number 30, The sequence shown in sequence number 31, The sequence shown in sequence number 38, A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 30, and having the same enhancer activity as the sequence shown in Sequence ID No. 30, A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 31, and having the same enhancer activity as the sequence shown in Sequence ID No. 31, or A sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 38, and having the same enhancer activity as the sequence shown in Sequence ID No.

38. The nucleic acid according to claim 1, having the following characteristics.

5. The nucleic acid according to claim 1, further comprising a promoter and a heterogeneous coding sequence.

6. The nucleic acid according to claim 5, wherein the nucleic acid is associated with a capsid containing PHP. eB, AAV-BR1, AAV-PHP. S, AAV-PHP. B, or AAV-PPS.

7. The nucleic acid according to claim 5, contained within a viral vector.

8. The nucleic acid according to claim 7, wherein the viral vector comprises a recombinant adeno-associated virus (AAV) vector.

9. The nucleic acid according to claim 5, wherein the nucleic acid further comprises or encodes a skipping element, the skipping element comprising T2A, P2A, E2A, F2A, or an internal ribosome entry site (IRES).

10. A transgenic cell comprising the nucleic acid described in Claim 5.

11. The transgenic cell according to claim 10, wherein the transgenic cell is a cortical excitatory neuron.

12. The gene-transformed cell according to claim 11, wherein the transgenic cell is a layer (L) 2, L3, L4, L5, or L6 cortical excitatory neuron.

13. The gene-transformed cell according to claim 11, wherein the transgenic cell is an L4 intracerebral (IT) cortical excitatory neuron, an L5 pyramidal tract (PT) cortical excitatory neuron, an L5 extracerebral (ET) cortical excitatory neuron, an L5 IT cortical excitatory neuron, an L5 projection (NP) cortical excitatory neuron, an L6 IT cortical excitatory neuron, an L6 cortical thalamic (CT) cortical excitatory neuron, or a Cajal-Retzius (CR) cortical excitatory neuron.

14. The transgenic cells according to claim 10, wherein the transgenic cells are derived from a subcortical population in the central nucleus of the amygdala (CEAc), substantia nigra compact region, hippocampal plateau, or prosbiculum (ProS).

15. The transgenic cell according to claim 10, wherein the transgenic cell is a CA1 pyramidal neuron, a dentate gyrus granule cell, a striatal neuron, or a cerebellar Purkinje cell.

16. An administerable composition comprising the nucleic acid described in claim 1 or 5.

17. The administerable composition according to claim 16, wherein the coding sequence codes for a fluorescent protein.

18. The administerable composition according to claim 16, wherein the coding sequence codes for a neurotransmitter, a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cell transport protein, a signaling molecule, a calcium reporter, a channelrhodopsin, a CRISPR / Cas molecule, an editase, a guide RNA molecule, a homologous recombination donor cassette, or DREADD.

19. The administerable composition according to claim 16, wherein the administerable composition is administered to a sample or subject by pipetting.

20. The administerable composition according to claim 19, wherein the pipetting is performed on a brain slice.

21. The administerable composition according to claim 20, wherein the brain slice comprises excitatory neurons.

22. The administerable composition according to claim 20, wherein the brain slice comprises cortical excitatory neurons of layers (L) 2, L3, L4, L5, and / or L6.

23. The administerable composition according to claim 20, wherein the brain slice comprises L4 IT cortical excitatory neurons, L5 PT cortical excitatory neurons, L5 ET cortical excitatory neurons, L5 IT cortical excitatory neurons, L5 NP cortical excitatory neurons, L6 IT cortical excitatory neurons, L6 CT cortical excitatory neurons, and / or CR cortical excitatory neurons.

24. The administerable composition according to claim 20, wherein the brain slice comprises CEAc, substantia nigra compact region, hippocampal platelet, and / or subcortical population in prosbiculum (ProS).

25. The administerable composition according to claim 20, wherein the brain slice comprises CA1 pyramidal neurons, dentate gyrus granule cells, striatal neurons, and / or cerebellar Purkinje cells.

26. The administerable composition according to claim 20, wherein the brain slices are derived from a mouse, a human, or a non-human primate.

27. ​​The administerable composition according to claim 16, wherein the administerable composition is administered to a living subject.

28. The administerable composition according to claim 27, wherein the biological target is a human, a non-human primate, or a mouse.

29. The administerable composition according to claim 27, wherein the administerable composition is administered to the biological subject by injection.

30. The administerable composition according to claim 29, wherein the injection includes intravenous injection, intraparenchymal injection, intraventricular (ICV) injection, intravesical Magna (ICM) injection, or subarachnoid injection.

31. An artificial expression construct selected from the group consisting of CN1427 (SEQ ID NO: 101), CN1818 (SEQ ID NO: 109), and CN2014 (SEQ ID NO: 2014).

32. A non-human transgenic animal comprising the nucleic acid described in Claim 5.

33. The non-human transgenic animal according to claim 32, wherein the non-human transgenic animal is a mouse or a non-human primate.

34. A method for selectively expressing a coding sequence in a population of neurons in vitro, comprising administering an administerable composition containing SEQ ID NO: 18 to a sample containing a population of neurons in a sufficient dose and for a sufficient amount of time, thereby selectively expressing the coding sequence in the population of neurons.

Images